NRx Pharmaceuticals, Inc. (NRXP) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Wilmington, DE, 美国. 现任CEO为 Jonathan C. Javitt.
NRXP 拥有 IPO日期为 2017-12-04, 2 名全职员工, 在 NASDAQ Global Market, 市值为 $43.56M.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
